XLO

Xilio Therapeutics, Inc.

NasdaqCMUSDEQUITY DELAYED

9.48

▲ 0.25 (2.72%)

MARKET · —

Price

Open

9.07

Prev close

9.23

Day high

9.23

Day low

9.11

Volume

5.12K

Market cap

—

P/E (TTM)

—

52W range

6.47 – 12.74

Trailing performance

Price return · vs SPY

Returnvs SPY

+0.65% +2.0%

+11.07% +7.3%

+7.64% +4.5%

+16.07% +5.0%

YTD

+3.01% -9.3%

-0.71% -20.7%

-76.33% -150.5%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

9.25

+2.53% from price

SMA 20

9.18

+0.50% from price

SMA 50

9.01

+2.45% from price

SMA 100

8.63

+9.90% from price

SMA 200

8.79

+4.99% from price

EMA 12

9.24

+2.64% from price

EMA 26

9.13

+3.83% from price

EMA 50

8.97

+5.71% from price

RSI (14)

53.6

Neutral

MACD (12,26,9)

0.11

Hist 0.01

ATR (14)

0.41

4.44% of price

Realised vol 30D

29.9%

Annualised

Bollinger upper

9.46

20, 2σ

Bollinger lower

8.91

20, 2σ

50 / 200 cross

Golden

9.01 vs 8.79

Trend bias

Above 200

+4.99%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.96

Less volatile than market

Correlation to SPY

0.26

Largely independent

Realised vol 30D

29.9%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-40.9%

Peak to trough

Max drawdown 5Y

-98.0%

Peak to trough

ATR 14

0.41

4.44% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 9.48

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

XLO · links out to the publisher

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates GlobeNewswire · 10d ago 3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership Simply Wall St. · 29d ago Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 47d ago Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer GlobeNewswire · 54d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.